All In Biotech

Drug Trial Radar · NCT01758081

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18

Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 25,874 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

25,874

Actual

Start

Jul 2010

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids affect risk of infection and plasma hCAP18 levels.

Conditions

  • Infections
  • Human Cathelicidin Antimicrobial Peptide (hCAP-18)

Interventions

  • vitamin D3Dietary supplement

    Vitamin D3 (cholecalciferol), 2000 IU per day

  • omega-3 fatty acids (fish oil)Drug

    Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

  • Vitamin D3 placeboDietary supplement

  • fish oil placeboDietary supplement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. upper respiratory infectionTime frame: one year
  2. hCAP-18Time frame: one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.